The Cosmetics has its Own Challenges
In parallel, the other multi-billion dollars business that is the cosmetics industry has also been facing significant problems. Originally dominated only by a few multinational corporations such as l'Oréal, Procter and Gamble, and Estée Lauder, their revenues have largely relied primarily on marketing rather than science-based efficacy. However, new factors (e.g., diversification of products such as anti-aging, skin whitening, men's products, etc.) and a few scandals (e.g., generalized use of chemicals suspected of endocrine disruption, carcinogenic effects, reproductive problems, etc.) have forced this industry to also review its model in recent years [8, 9] .
Common Strategies and Technologies on the Rise -Multi -Targets and Combined Active Ingredients
For the pharmaceutical industry, increasing the life time of older products and off-patent molecules has clearly become a trend in response to recent challenges [10] . One way to achieve that has been with new drug combinations or so-called fixed-dose combination (FDC) products. In the specific therapeutic areas of asthma, HIV, cancer or diabetes, FDCs have played a pivotal role to achieve greater efficacy and sustained revenues (e.g., Atripla ® , Advair ® , Janumet ® , etc.). FDCs are products that comprise at least two (often more) active pharmaceutical ingredients (APIs) combined in a single dosage form with fixed doses. New intellectual property, comparable safety, increased compliance and efficacy, as well as sustained or increased revenues are associated with the 'multi-target' approach that constitute FDCs [10] [11] [12] [13] . For other complex therapeutic areas such as CNS diseases and disorders, the trend is more recent. Nonetheless, as of 2013, FDCs have been shown to constitute 22% of the CNS pipeline in development according to a report published recently by Drug Development [12] . The rationale is simple-administration of more than one drug or molecule for treating a disease leads to multiple actions that can be additive or synergistic [14, 15] . Comparable approaches are increasing been used by the cosmetic sector. Some dermatological products with anti-aging effects or against pathological problems such as chronic xerosis, psoriasis, and pruritus are now also relying on combinatorial approaches using clinically-proven ingredients with scientifically-demonstrated efficacy [16, 17] . This relatively new use of science applied to cosmetic/ skin products has generated its own specialized line of products -cosmeceuticals. For cosmeceutical products that comprise, for safety reasons, mainly ingredients of organic origin, a corresponding terminology, biocosmeceuticals, has even been introduced recently [16] .
Concluding Remarks
Using known and safe molecules for which demonstration of efficacy (scientifically and clinically) and additive or synergistic effects have been shown will undoubtedly support the development of innovative next generation products. For these two large industries, the cost-effectiveness of this combinatorial approach will also probably ease and accelerate the approval of new technologies that better meet the medical needs of patients and users.
